Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANI PHARMACEUTICALS INC Director's Dealing 2018

Mar 5, 2018

31676_dirs_2018-03-05_521d7a9e-28cd-4cc9-9e73-b31ae72ae1e3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2018-03-01

Reporting Person: Schrepfer Robert W (SVP - New Bus Dev & Spec Sales)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-01 Common Stock M 18750 $28.76 Acquired 41590 Direct
2018-03-01 Common Stock S 5498 $60.33 Disposed 36092 Direct
2018-03-01 Common Stock S 10800 $61.64 Disposed 25292 Direct
2018-03-01 Common Stock S 11954 $62.25 Disposed 13338 Direct
2018-03-01 Common Stock S 400 $63.07 Disposed 12938 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-03-01 Stock Option $28.76 M 18750 Disposed 2024-08-19 Common Stock (18750) Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $61.00 to $61.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date of the options was August 20, 2014.